✦ LIBER ✦

Treatment with infliximab of pityriasis rubra pilaris refractary to conventional therapy in a patient with concurrent chronic hepatitis B viral infection

Book ID: 116582850
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 61 KB
Volume: 56
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2006.10.817

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictive model of response to therapy

Predictive model of response to therapy with interferon in patients with chronic hepatitis B virus infection: A methodological note

✍ Gioacchino Leandro; M. G. Brook; P. Karayiannis; H. C. Thomas 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 2 views

Apolipoprotein B-associated cholesterol

Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin

✍ D. A. SHERIDAN; D. A. PRICE; M. L. SCHMID; G. L. TOMS; P. DONALDSON; D. NEELY; M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

A mutation in the interferon sensitivity

A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1b

✍ Mutsumi Murayama; Yoshiaki Katano; Isao Nakano; Masatoshi Ishigami; Kazuhiko Hay 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 2 views

## Abstract The interferon sensitivity‐determining region (ISDR) is useful as a predictive marker of the response to interferon (IFN) therapy for chronic hepatitis patients with a Japan‐specific subtype (J‐type) of hepatitis C virus (HCV) genotype 1b. This marker is not useful for predicting respon

Treatment with peginterferon alfa-2a (40

Treatment with peginterferon alfa-2a (40KD) (PEGASYS®) results in improved rates of response compared to conventional interferon in patients with HBEAG positive chronic hepatitis B harboring HBV genotypes B or ‘difficult-to-treat’ genotype C

✍ W.G.E. Cooksley; M.-Y. Lai; T. Piratvisuth; Y.-J. Wang; V. Mahachai; Y.-C. Chao; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Combination therapy of thymalfasin (thym

Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment

✍ VINOD RUSTGI 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB

Plasma hepatitis C virus (HCV) RNA is co

Plasma hepatitis C virus (HCV) RNA is comparable to hepatic HCV RNA when obtained while on therapy at the end of treatment as a predictor of sustained response in patients with chronic hepatitis C infection

✍ Lino J. Deguzman; Jose M. Nieto; Shelley A. Deguzman; Andrew Conrad; Bradley Col 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 176 KB